GLP-1 Metabolic Medicine

Physician-prescribed GLP-1 receptor agonist therapy for weight loss and metabolic optimisation, delivered as part of LIFT Clinic's evidence-based MetaboLIFT® protocol with ongoing medical monitoring.

LIFT Clinic's approach to GLP-1 receptor agonist therapy is embedded within a comprehensive medical framework rather than offered as a standalone prescription service. Dr. Tyler Lim prescribes GLP-1 medications — including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) — only where clinically indicated, following a thorough metabolic assessment that includes blood biomarker testing, body composition analysis, and a review of the patient's health history and goals. GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite — resulting in meaningful and sustained weight loss when combined with lifestyle modification. At LIFT Clinic, GLP-1 therapy is integrated into the MetaboLIFT® 12-week programme, meaning patients receiving these medications are simultaneously supported by daily coaching, nutrition therapy, and regular medical reviews. This reduces the risk of muscle mass loss (a common concern with rapid pharmacological weight loss) through concurrent resistance training and protein-optimised nutrition protocols. Dosing is titrated progressively under medical supervision, with monthly doctor consultations to assess tolerability and progress. The inclusion of GLP-1 medications in the programme fee — where prescribed — removes the financial ambiguity common in medispa settings and ensures that pharmacological and lifestyle interventions are genuinely integrated.